Patients with minimal change nephrotic syndrome (MCNS) frequently have suppressed in vivo and in vitro immune responsiveness of uncertain etiology. Because increased suppressor cell activity has been associated with this disease, urines from MCNS patients were screened for activity of the lymphokine soluble immune response suppressor (SIRS), a product of concanavalin A-or interferon-activated suppressor T cells. Urines from untreated MCNS patients suppressed polyclonal plaque-forming cell responses of cultured splenocytes. This suppressive activity was identified as human SIRS by the following functional and physical criteria: (a) molecular weight estimated by gel filtration; (b) kinetics of suppression; (c) inhibition of suppression by catalase, levamisole, and 2-mercaptoethanol; (d) abrogation of activity by acid or protease treatment; (e) elution pattern on high performance liquid chromatography; and (f) cross-reactivity with monoclonal antimurine SIRS antibodies. Suppressive activity disappeared from urine after initiation of treatment but before remission of symptoms. Urines were tested from 11 patients with MCNS, all of whom excreted SIRS. In addition, two nephrotic patients with acute glomerulonephritis and three nephrotic patients with membranoproliferative disease excreted SIRS, but other nephrotics and all nonnephrotic patients did not. These results indicate that excretion of SIRS occurs in certain cases of nephrotic syndrome and that the presence of SIRS in the urine is not accounted for solely by the presence of proteinuria or nephrosis. Serum from four nephrotic patients also contained SIRS, whereas neither serum nor urine from six normal subjects contained SIRS activity. The systemic presence of SIRS in these four patients, and the identification of SIRS in urines from a larger group of patients, suggest a possible role for SIRS in the suppressed immune responses often found in nephrotic syndrome.
Introduction
The nephrotic syndrome (NS)' is characterized by extensive urinary loss of albumin leading to hypoalbuminemia, edema, 1 . Abbreviations used in this paper: CNBr, cyanogen bromide; Con A, concanavalin A; HPLC, high performance liquid chromatography; and hypercholesterolemia (1) . Patients with this syndrome frequently have suppressed clinical and in vitro immune responsiveness; the disease in which this phenomenon has been most extensively studied is minimal change nephrotic syndrome (MCNS) . Unique attributes of MCNS include the lack of morphologic changes sufficient to account for proteinuria, the observed pattern of glomerular permselectivity (2) , a frequent association with antecedent immunogenic stimuli (3) , and the marked responsiveness of this disease to immunomodulatory agents. Patients with minimal change disease and other forms of NS show evidence of decreased cellular immunity (4) . Furthermore, MCNS patient sera have been found to suppress lymphocyte proliferation (5) and to show cytotoxic activity (6) . Enhanced suppressor cell function has also been described (7) . Thus, clinical evidence of altered immunity appears to be associated with increased suppressor cell activity.
Suppressor cells have been shown in most in vitro model systems to act through release of soluble suppressor factors. One such system that has been well characterized is the soluble immune response suppressor (SIRS) pathway. SIRS is a product of mitogen- (8) or interferon-activated (9) murine or human (10) suppressor T lymphocytes that inhibits production of antibody when added at or near initiation of lymphocyte cultures. Suppression also occurs when factor is added late in the culture period after activation to its suppressive form, SIRSO,, by reaction with low concentrations of H202 (11) .
Human SIRS has a molecular weight of 110,000-150,000 by chromatography on Sephacryl S-200 gel when eluted with buffers of physiologic ionic strength and 10,000-15,000 when eluted with high ionic strength buffers. It is acid and protease sensitive, and its in vitro activity is blocked by levamisole and catalase, which block activation of SIRS to SIRS0., and by 2- mercaptoethanol (2-ME), which inactivates SIRSO. (10) . Inhibition of suppression by these reagents and activation by peroxide are characteristic of both murine and human SIRS and are useful techniques in screening for the presence of SIRS in other systems (9) .
To determine whether nephrotic patients might produce SIRS, we evaluated urines from children with MCNS in relapse and other proteinuric renal diseases for suppressive activity. Urine from all patients with MCNS and certain other nephrotic patients suppressed in vitro antibody-producing responses. This immunosuppressive activity was identical to human SIRS by functional and physical criteria. Suppressive activity disappeared from the urine after initiation of treatment, but before remission of NS. These results show that urines from certain nephrotic children contain the suppressor lymphokine SIRS. (12) .
Assay for antibody production. Human spleen cells were obtained aseptically from cadaver kidney transplant donors at the time of organ harvest, processed as described previously (1 1 Absorption of immunosuppressive activity using monoclonal antimurine SIRS antibodies. Monoclonal antimurine SIRS antibodies were obtained as described previously (16) . Briefly, partially purified murine SIRS (5 x l0 U) in complete Freund's adjuvant was injected into Sprague-Dawley rats at biweekly intervals. Serum from each rat was bound to cyanogen bromide (CNBr)-activated Sepharose 6B (Sigma Chemical Co.), and the coupled beads were tested for ability to absorb murine SIRS activity from a standard solution (103 U/ml). Spleen cells from a rat demonstrating high-serum anti-SIRS activity were fused to the myeloma cell line SP 2/0 and supernates from hybridoma wells were tested for ability to absorb murine SIRS activity as described above. Four hybridomas producing antimurine SIRS antibody have been cloned. Each monoclonal antibody was coupled to CNBr-activated Sepharose 6B. A suspension of urine showing suppressive activity was incubated with the beads for I h at 40C. After removal of the beads by centrifugation the urine was tested for SIRS activity.
Results
Suppression of PFC response by urines from patients with MCNS. Resuspended urines were assayed for suppressive activity by adding graded amounts to PWM-stimulated lymphocytes 24 h after culture initiation. PFC responses were determined on day 7. Table I shows results of a typical experiment. Addition of urine from a healthy volunteer to which human serum albumin (1 mg/ml) had been added before processing did not significantly affect responses. However, 50 Ml of urine from the four patients with MCNS, corresponding to 5% of culture volume, suppressed responses by over 70%. The suppressive activity was not accounted for by a general cytotoxic effect of the urine in that a decrease in cell number and/or viability proportional to the reduction in PFC response was not observed.
Molecular weight ofsuppressor substance. To approximate the size of the suppressive moiety, urine with known suppressive activity was fractionated by gel filtration using Sephacryl S-200 chromatography. Fig. 1 shows the results of experiments (17) .
Screening of urine for SIRS using characteristics of the SIRS pathway. Because of similarities between the migration patterns for SIRS and urine suppressive activity, the urine fractions from S-200 column chromatography which contained suppressive activity were pooled and screened for SIRS activity by using several characteristics of the SIRS pathway. To evaluate the kinetics of suppression and potential activation by peroxide, urine factor was added on day I or 6 to 7-d lymphocyte cultures. In the experiment shown in Table II , urine factor added early in the culture period suppressed PFC responses by 60%. On day 6, addition of urine factor did not cause suppression; however, urine factor reacted with 10-6M H202 for 20 min before addition to culture suppressed responses as well as factor added on day 1. All five urines tested showed titratable activity on day 6 after reaction with peroxide. Adding peroxide-treated medium on day 6 did not significantly affect responses.
Cultures were also tested to determine whether addition of levamisole, catalase, and 2-ME blocked suppression by the urine factor. ,Ml of the urine factor on day 1. Addition of 5 ;ig levamisole on day 1 blocked suppression in cultures containing the urine factor, as did addition of catalase (5,000 U) or 2-ME (10-4M) on day 3. Addition of levamisole, catalase, or 2-ME alone did not significantly affect responses.
To determine whether the urine factor was inactivated by acidification to pH 2 or by incubation with protease, factor was acidified to pH 4 or pH 2 with HCO, then neutralized after 3 h at 4°C. Alternatively, urine was incubated with protease (Proteinase, Sigma Chemical Co.), 10 Mg/ml for 3 h at 40C. All solutions were sterilized before addition to culture on day 1. In the experiment shown in Table IV , acidification to pH 4 had no effect on suppressive activity, but acidification to pH 2 resulted in a loss of activity. Similarly, the urine factor was inactivated by protease. Thus, the ability of H202 to activate the urine factor to suppress responses when added shortly before culture assay, inhibition of suppression by agents that inhibit SIRS activity, and pH and protease sensitivity of the urine suppressive activity are all identical to those described for human lymphocyte SIRS. Taken together with the apparent molecular weight of the urine factor in physiologic and high ionic strength buffers, these data strongly support the possibility that suppressive activity of MCNS urine is due to the presence of SIRS.
Fractionation of urine suppressor factor by HPLC. Urine with suppressive activity and human lymphocyte SIRS obtained from concanavalin A (Con A)-activated PBMC were fractionated by reverse-phase HPLC on an RP-8 (10 MM) analytical column. Protein was eluted by an increasing gradient of npropanol. Fig. 2 compares the separation of biologic activity and protein for lymphocyte SIRS (upper panel) and for urine SIRS (lower panel). In both experiments, SIRS activity was separated from the major protein peaks present. Two major SIRS peaks eluted at the 5% propanol step-up and at 18% propanol on the linear gradient. A smaller, third peak of SIRS activity eluted at 8-9% propanol. All of the SIRS bound to the column; none was detected in the initial flow-through during column loading. Further, all activity loaded on the RP-8 column was recovered in the three active peaks; no SIRS activity was eluted by higher propanol concentration or by extended elution times. Identical findings were obtained with three different urines. The elution patterns from HPLC suggest that the urine SIRS and lymphocyte SIRS are similar proteins. Untreated factor 4,100 pH 4 3,800 pH 2 10,750 Protease 8,300 * Urines were treated by adjusting pH to 4 Use of monoclonal antimurine SIRS antibodies to absorb urine suppressive activity. Four monoclonal antibodies to murine SIRS are available. Lymphocyte SIRS and urine SIRS were incubated with Sepharose beads coupled to each of the antimurine SIRS antibodies to determine whether suppressive activity was absorbed from the solution. Table V Three nephrotic patients with type I membranoproliferative glomerulonephritis showed considerable suppressive activity in their urine, with a mean of 57 U/ml. Suppression from one of these urines was confirmed as SIRS-mediated by all the criteria described above, including antibody absorption. After treatment with steroids, two patients became nonnephrotic; in one, steroids were discontinued. During remission of nephrosis neither patient excreted SIRS in the urine, although persistent proteinuria and hypocomplementemia indicated that the primary nephritic process was still active.
Urines were obtained from four patients with apparent acute glomerulonephritis. Three of these patients were biopsied because of atypical features which included mild nephrotic syndrome. Two of the biopsied patients (one diagnosed morphologically as having immune complex nephritis, the other, "nephritis with omniglomerular sclerosis") had small amounts of suppressive activity (5 and 17 U/ml, respectively).
Neither of two patients with focal glomerulosclerosis had urine SIRS despite massive proteinuria. Urine from two nonnephrotic children with systemic lupus erythematosus who were proteinuric did not contain SIRS. One patient each with diabetic nephropathy, congenital nephrosis, and transient proteinuria of undetermined etiology (not nephrotic) also had no urinary SIRS activity.
Assay of serum for SIRS activity. Because some patients with nephrosis manifest decreased in vivo and in vitro immune responses, sera were evaluated to determine whether SIRS activity may be present systemically in patients who excrete SIRS. The suppressive effect of patient sera on in vitro PFC responses was assayed in a manner identical to that used in screening urines. Sera from all three patients with MCNS who were tested showed suppressive activity, with a mean of 83 U/ml (Table VIII) . The serum from a patient with membranoproliferative glomerulonephritis also contained SIRS, 115 U/ (5, 24, 25) . A heat-stable substance in patient serum has been described which binds to normal lymphocytes and decreases the proliferative response to mitogens (26) . Increased Con A-activated suppressor cell activity has also been reported in MCNS patients in relapse compared to healthy controls, patients in remission, and patients with glomerulonephritis (7). Although these findings appear most striking in MCNS, they may not be restricted to minimal change disease; several of the studies cited above found similar abnormalities in other forms of nephrotic syndrome (6, 21, 22, (24) (25) (26) . Despite this considerable body of evidence, the mechanism of immune suppressive activity is unclear. It has been suggested that suppression could be a nonspecific effect of the elevated serum lipid levels seen in these patients (27) . An agent that has a demonstrable role in basic immunoregulatory systems has not previously been associated with nephrotic syndrome. Because patients with MCNS have elevated Con A-activated suppressor T cell activity and because it is known that Con A-activated suppressor T cells release the lymphokine, SIRS, it seemed appropriate to seek evidence of SIRS production in these patients.
The SIRS suppressor pathway has been studied extensively in mice, and murine SIRS has been purified to homogeneity (17) . In addition to its effect on antibody secretion, it also inhibits cell division and protein secretion by a variety of normal and neoplastic cell lines (10) . Further, SIRS blocks guanosine triphosphate-dependent microtubule assembly in vitro (28) . Thus, its effects are not limited to regulation of the immune system. Human SIRS, although not as well characterized, has been investigated sufficiently to establish that it constitutes an analogue ofthe murine system. Both lymphokines have characteristic kinetics of suppression and share certain physicochemical properties. Also, catalase, levamisole, and 2-ME interfere with suppression in both systems. Employed together, these characteristics constitute an effective tool for screening for murine (10) or human (11) SIRS activity in various in vitro models of immunosuppression.
To determine whether SIRS was produced by patients with NS, urines of MCNS patients were evaluated for ability to suppress PFC responses. Suppressive activity was found in urines from all patients with SRNS in relapse. Table IX summarizes characterization of this suppressive activity and compares the urine factor to human lymphocyte SIRS. The two factors have similar migration patterns on gel filtration with physiologic and high ionic strength buffers. HPLC of each factor is identical, yielding two larger peaks accounting for -80% of total activity at 5% and 18% propanol, respectively, and a smaller peak at 8-9% propanol. Both t Urines were obtained from these patients before occurrence of a significant decrease in protein excretion (see Table VI ).
The exact nature of this relationship is unclear. However, abnormal immune responses in MCNS, the sensitivity of this disease to immunomodulatory agents, and remission of nephrosis with inhibition of cell-mediated immunity led Shalhoub (33) to propose that MCNS is a primary immunologic disorder with renal manifestations. Furthermore, experimental evidence has indicated that lymphocytes may mediate depletion of glomerular polyanion (34) , the component of the glomerular filter that retards albumin excretion (35) ; and that macrophages may mediate experimentally induced albuminuria (36, 37) . Thus, it is of interest that levamisole, an inhibitor of the SIRS pathway, has been found to induce remission of MCNS (38) . The disappearance of SIRS activity with steroid treatment, before entry into remission, may only indicate that urinary SIRS is a steroid-sensitive epiphenomenon of conditions that relate to and possibly precede clinical nephrotic syndrome. However, because SIRS affects cells outside the immune system, these data are also consistent with the possibility that SIRS may be involved in the pathogenesis of some cases of nephrotic syndrome. Further investigation may clarify the relationship of SIRS production to the disease state in these patients.
